secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001493152-24-043821
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa Pharmaceuticals replaces auditor BD & Co. with Cherry Bekaert
----------------------------------------------------------------------

- BD & Co. resigned Oct 31, 2024 after merger into Citrin Cooperman; no disagreements or reportable events.
- Audit Committee appointed Cherry Bekaert LLP for FY 2024 and subsequent interim periods.
- No prior consultations with Cherry Bekaert regarding accounting principles or disagreements.
- BD & Co.'s audit reports for 2023 and 2022 were unqualified and contained no adverse opinion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224043821/0001493152-24-043821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224043821/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer